HeartBeam Inc. Expands Leadership and Announces CEO as Director
May 5, 2025 — HeartBeam Inc., a leading medical technology company specializing in telemedicine solutions for cardiac care, has announced a significant change in its corporate governance structure. The company has expanded its board of directors and appointed its current CEO as a director. This strategic move aims to strengthen leadership and enhance decision-making capabilities as HeartBeam continues to grow its global presence in the health care sector.
HeartBeam Inc., headquartered in Santa Clara, United States, operates on the Nasdaq stock exchange. The company focuses on revolutionizing cardiovascular disease management through remote monitoring and diagnosis technologies. With a market capitalization of $59,020,000 and a recent close price of $1.81 on May 1, 2025, HeartBeam has shown resilience despite fluctuations in its stock price, which reached a 52-week high of $3.48 on December 15, 2024, and a low of $1.45 on April 6, 2025.
Key Financials:
- Close Price (2025-05-01): $1.81
- 52 Weeks High: $3.48 (2024-12-15)
- 52 Weeks Low: $1.45 (2025-04-06)
- Market Cap: $59,020,000
- Price Earnings Ratio: -2.4
The company’s mission is to provide innovative telemedicine solutions that enable remote monitoring and diagnosis of heart health, serving customers worldwide through its website, www.heartbeam.com .
FDA Fast Track Designation for Ichnos Glenmark Innovation
In related health care news, Ichnos Glenmark Innovation (IGI), a biotechnology company focused on oncology, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, ISB 2001. This designation is for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
ISB 2001 is a trispecific antibody therapeutic targeting BCMA and CD38 on myeloma cells and CD3 on T cells. The drug is currently in a Phase 1 dose-expansion study, with results from the dose-escalation portion to be presented at the 2025 ASCO Annual Meeting. This Fast Track designation underscores the potential of ISB 2001 to address unmet medical needs in the treatment of multiple myeloma.
For more information on HeartBeam Inc., visit www.heartbeam.com .